Polycyclic organic compounds, Cyclopropanes, Antineoplastic and immunomodulating drugs, Organohalides
Cyclic compounds (1)
Zosuquidar Trihydrochloride (167465-36-3)
Zosuquidar (also LY-335979) is an experimental antineoplastic drug. In 2010, it was announced that a phase III trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome did not meet its primary endpoint and Eli Lilly discontinued its development. Zosquidir inhibits P-glycoproteins.